Inovio Pharmaceuticals Inc - Company Profile

Powered by

All the data and insights you need on Inovio Pharmaceuticals Inc in one report.

  • Save hours of research time and resources with
    our up-to-date Inovio Pharmaceuticals Inc Strategy Report

  • Understand Inovio Pharmaceuticals Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Inovio Pharmaceuticals Inc: Overview

Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; and INO-3107 for recurrent respiratory papillomatosis (RRP). The company is also engaged in development programs in partnership with several companies and government bodies to develop therapeutics for infectious diseases such as HIV, Ebola, Zika virus, Middle East respiratory syndrome (MERS), Lassa fever and COVID-19. Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.

Gain a 360-degree view of Inovio Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of Inovio Pharmaceuticals Inc and make more informed decisions for your business Find out more
Headquarters United States of America

Address Suite 110, 660 W. Germantown Pike, Plymouth Meeting, Pennsylvania, 19462


Telephone 267 440 4200

No of Employees 184

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange INO (NASD)

Revenue (2023) $10.3M -91.9% (2023 vs 2022)

EPS XYZ

Net Income (2023) XYZ 51.7% (2023 vs 2022)

Market Cap* $250.9M

Net Profit Margin (2023) XYZ -495.6% (2023 vs 2022)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Inovio Pharmaceuticals Inc premium industry data and analytics

90+

Catalyst Calendar

Proactively evaluate Inovio Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

70+

Clinical Trials

Determine Inovio Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

70+

Pipeline Drugs

Identify which of Inovio Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

18+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

14+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products Brands
Pipeline products: -
COVID-19: dMAb
INO-4800 SynCon
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Inovio Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand Inovio Pharmaceuticals Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Contracts/Agreements In January, the company and Coherus BioSciences entered into a clinical collaboration and supply agreement to assess the combination of INO-3112 and LOQTORZI (toripalimab-tpzi) as a potential to treat patients with locoregionally advanced, high-risk, HPV16/18.
2023 Regulatory Approval In September, the company announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation for INO-3107 as a potential treatment for patients with Recurrent Respiratory Papillomatosis.
2023 Regulatory Approval In May, the company announced that the European Commission (EC) granted orphan drug designation for INO-3107.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Inovio Pharmaceuticals Inc Merck & Co Inc Pfizer Inc Sanofi GSK plc
Headquarters United States of America United States of America United States of America France United Kingdom
City Plymouth Meeting Kenilworth New York Paris Brentford
State/Province Pennsylvania New Jersey New York Ile-de-France England
No. of Employees 184 72,000 88,000 87,994 70,212
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Simon X. Benito Chairman Executive Board 2019 78
Jacqueline E. Shea, Ph.D. Chief Executive Officer; Director; President Executive Board 2022 -
Peter D. Kies Chief Financial Officer Senior Management 2002 59
Michael Sumner Chief Medical Officer Senior Management 2022 -
Laurent Humeau, Ph.D. Chief Scientific Officer Senior Management 2019 56
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Inovio Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into Inovio Pharmaceuticals Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward